Lonza, Moderna Further Collaborate for Covid-19 Vaccine Moderna

The Netherlands: Drug Substance Manufacturing Lonza, Moderna Further Collaborate for Covid-19 Vaccine Moderna

24.06.2021Editor: Ahlam Rais

Lonza has expanded its collaboration with Moderna for drug substance manufacturing of the Covid-19 Vaccine Moderna. A new drug substance manufacturing line will also be installed at Lonza’s Geleen site in the Netherlands.

Related Companies

Lonza Ltd.

Moderna Inc.

TRM Filter d.o.o.

Frewitt fabrique de machines SA

EPC Group

The new drug substance production line will complement the existing production network and support the manufacture of up to an additional 300 million doses per year.
(Source: Pixabay)

Basel/Switzerland – Lonza has recently announced the expansion of its collaboration with Moderna. The expanded collaboration will further extend the manufacture of the drug substance for the Covid-19 Vaccine Moderna and provides for the installation of a new manufacturing line for drug substance production at Lonza’s Geleen site in the Netherlands.

The new production line in Geleen will complement Lonza’s existing drug substance production network for Covid-19 Vaccine Moderna and deliver a crucial manufacturing step to increase overall drug substance output. As such, the new production line will contribute to the supply of up to an additional 300 million doses per year, at a 50ug dose, once operating at full capacity.

The new production line in Geleen, the Netherlands is expected to be operational by the end of 2021.

In May 2020, Lonza and Moderna announced a ten-year strategic collaboration agreement to enable the manufacture of Moderna’s Covid-19 vaccine and additional Moderna products in the future. Since then, Lonza has installed three production lines at its Visp (CH) site and one production line in Portsmouth, USA. In April 2021, Lonza and Moderna entered a new agreement to add three further production lines at its Visp (CH) site.

Lonza will leverage its existing infrastructure in Geleen, the Netherlands to provide fast build-out and ramp-up of operations.

Unfold for details of your consent

Stand vom 23.03.2021

Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.

Consent to the use of data for promotional purposes

I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planckstr. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here

Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.

In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here.

Right of revocation

I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://support.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.

(ID:47479091)

The Netherlands: Drug Substance Manufacturing Lonza, Moderna Further Collaborate for Covid-19 Vaccine Moderna

Subscribe to the newsletter now

Don't Miss out on Our Best Content

Consent to the use of data for promotional purposes